Cargando…

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope

Antibodies have been widely used for cancer therapy owing to their ability to distinguish cancer cells by recognizing cancer-specific antigens. Epidermal growth factor receptor (EGFR) is a promising target for the cancer therapeutics, against which several antibody clones have been developed and bro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makabe, Koki, Yokoyama, Takeshi, Uehara, Shiro, Uchikubo-Kamo, Tomomi, Shirouzu, Mikako, Kimura, Kouki, Tsumoto, Kouhei, Asano, Ryutaro, Tanaka, Yoshikazu, Kumagai, Izumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952593/ https://www.ncbi.nlm.nih.gov/pubmed/33707468 http://dx.doi.org/10.1038/s41598-021-84171-3

Ejemplares similares

Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity
por: Asano, Ryutaro, et al.
Publicado: (2018)

Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation
por: Kuwahara, Atsushi, et al.
Publicado: (2020)

Construction of IgG–Fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction
por: Yamada, Risa, et al.
Publicado: (2023)

Epigenetic mechanisms to propagate histone acetylation by p300/CBP
por: Kikuchi, Masaki, et al.
Publicado: (2023)

Structural insight into microtubule stabilization and kinesin inhibition by Tau family MAPs
por: Shigematsu, Hideki, et al.
Publicado: (2018)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014)

Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
por: Goulet, Dennis R., et al.
Publicado: (2022)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Cryo-EM structure of the human ELMO1-DOCK5-Rac1 complex
por: Kukimoto-Niino, Mutsuko, et al.
Publicado: (2021)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
por: Kagawa, Yosuke, et al.
Publicado: (2023)

Anti‐EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half‐life
por: Asano, Ryutaro, et al.
Publicado: (2016)

ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells
por: Kol, Arjan, et al.
Publicado: (2017)

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
por: Kunimasa, Kei, et al.
Publicado: (2022)

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
por: Cappuzzo, F, et al.
Publicado: (2008)

Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells
por: FUKUDA, KAZUMASA, et al.
Publicado: (2011)

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
por: Zhang, Lianhai, et al.
Publicado: (2013)

NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer
por: Yang, Guang, et al.
Publicado: (2021)

Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells
por: Kimura, Kouki, et al.
Publicado: (2023)

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
por: Reade, Chad A, et al.
Publicado: (2009)

Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles
por: Qian, Yichun, et al.
Publicado: (2014)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016)

Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab
por: Liu, Shujie, et al.
Publicado: (2022)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats
por: Asano, Ryutaro, et al.
Publicado: (2020)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

EGFR-dependent phosphorylation of leucine-rich repeat kinase LRRK1 is important for proper endosomal trafficking of EGFR
por: Ishikawa, Kouki, et al.
Publicado: (2012)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab
por: Sun, Chaonan, et al.
Publicado: (2017)

PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer
por: Luo, Maochao, et al.
Publicado: (2021)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Existence of two O-like intermediates in the photocycle of Acetabularia rhodopsin II, a light-driven proton pump from a marine alga
por: Tamogami, Jun, et al.
Publicado: (2017)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells
por: Ming Lim, Chwee, et al.
Publicado: (2013)

Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab
por: He, Xuzhi, et al.
Publicado: (2018)

Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer
por: Nair, Sindhu, et al.
Publicado: (2020)

FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer
por: Mu, Lan, et al.
Publicado: (2022)

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma
por: Chaudhary, Ritu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_90lv9qfdlunttop8f6ru9f2bfj